Ionis Pharmaceuticals Wins CHMP Backing for DAWNZERA in Hereditary Angioedema Prevention

Reuters

Nov 14, 2025

Ionis Pharmaceuticals Wins CHMP Backing for DAWNZERA in Hereditary Angioedema Prevention

Ionis Pharmaceuticals Inc. announced that the Committee for Medicinal Products for Human Use $(CHMP)$ of the European Medicines Agency has issued a positive opinion recommending approval of DAWNZERA™ (donidalorsen) for the routine prevention of recurrent attacks of hereditary angioedema $(HAE)$ in adults and adolescents aged 12 years and older. The recommendation is based on robust clinical evidence from the Phase 3 OASIS-HAE and OASISplus studies, which demonstrated significant reductions in HAE attack rates. The final approval decision now rests with the European Commission, with a decision expected in the first quarter of 2026. Otsuka Pharmaceutical Co., Ltd. holds exclusive rights to bring donidalorsen to patients in Europe and Asia Pacific.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251113183682) on November 14, 2025, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2583250878"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583250878\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583250878?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583250878","market":"nz","top_or_hot":-1,"title":"Ionis Pharmaceuticals Wins CHMP Backing for DAWNZERA in Hereditary Angioedema Prevention","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ionis Pharmaceuticals Wins CHMP Backing for DAWNZERA in Hereditary Angioedema Prevention\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ionis Pharmaceuticals Inc. announced that the Committee for Medicinal Products for Human Use <a href=\"https://laohu8.com/S/CHMP\">$(CHMP)$</a> of the European Medicines Agency has issued a positive opinion recommending approval of DAWNZERA™ (donidalorsen) for the routine prevention of recurrent attacks of hereditary angioedema <a href=\"https://laohu8.com/S/HAE\">$(HAE)$</a> in adults and adolescents aged 12 years and older. The recommendation is based on robust clinical evidence from the Phase 3 OASIS-HAE and OASISplus studies, which demonstrated significant reductions in HAE attack rates. The final approval decision now rests with the European Commission, with a decision expected in the first quarter of 2026. Otsuka Pharmaceutical Co., Ltd. holds exclusive rights to bring donidalorsen to patients in Europe and Asia Pacific.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251113183682) on November 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ionis Pharmaceuticals Wins CHMP Backing for DAWNZERA in Hereditary Angioedema Prevention</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIonis Pharmaceuticals Wins CHMP Backing for DAWNZERA in Hereditary Angioedema Prevention\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-14 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ionis Pharmaceuticals Wins CHMP Backing for DAWNZERA in Hereditary Angioedema Prevention\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ionis Pharmaceuticals Inc. announced that the Committee for Medicinal Products for Human Use <a href=\"https://laohu8.com/S/CHMP\">$(CHMP)$</a> of the European Medicines Agency has issued a positive opinion recommending approval of DAWNZERA™ (donidalorsen) for the routine prevention of recurrent attacks of hereditary angioedema <a href=\"https://laohu8.com/S/HAE\">$(HAE)$</a> in adults and adolescents aged 12 years and older. The recommendation is based on robust clinical evidence from the Phase 3 OASIS-HAE and OASISplus studies, which demonstrated significant reductions in HAE attack rates. The final approval decision now rests with the European Commission, with a decision expected in the first quarter of 2026. Otsuka Pharmaceutical Co., Ltd. holds exclusive rights to bring donidalorsen to patients in Europe and Asia Pacific.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251113183682) on November 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IONS","symbol_name":"Ionis Pharmaceuticals, Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL950lV3:1","article_id":"2583250878","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583250878","pubTimestamp":1763121634,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ionis Pharmaceuticals Inc. announced that the Committee for Medicinal Products for Human Use  of the European Medicines Agency has issued a positive opinion recommending approval of DAWNZERA  for the routine prevention of recurrent attacks of hereditary angioedema  in adults and adolescents aged 12 years and older. The recommendation is based on robust clinical evidence from the Phase 3 OASIS-HAE and OASISplus studies, which demonstrated significant reductions in HAE attack rates. The final approval decision now rests with the European Commission, with a decision expected in the first quarter of 2026. Otsuka Pharmaceutical Co., Ltd. holds exclusive rights to bring donidalorsen to patients in Europe and Asia Pacific.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, i","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IONS":"Ionis Pharmaceuticals, Inc","BK4139":"生物科技"},"translate_title":"Ionis Pharmaceuticals为DAWNZERA预防遗传性血管性水肿赢得CHMP支持","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IONS":0.9},"content_text":"Ionis Pharmaceuticals Wins CHMP Backing for DAWNZERA in Hereditary Angioedema Prevention\n    \n\n        Ionis Pharmaceuticals Inc. announced that the Committee for Medicinal Products for Human Use $(CHMP)$ of the European Medicines Agency has issued a positive opinion recommending approval of DAWNZERA™ (donidalorsen) for the routine prevention of recurrent attacks of hereditary angioedema $(HAE)$ in adults and adolescents aged 12 years and older. The recommendation is based on robust clinical evidence from the Phase 3 OASIS-HAE and OASISplus studies, which demonstrated significant reductions in HAE attack rates. The final approval decision now rests with the European Commission, with a decision expected in the first quarter of 2026. Otsuka Pharmaceutical Co., Ltd. holds exclusive rights to bring donidalorsen to patients in Europe and Asia Pacific.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251113183682) on November 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}